Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma
Table 2
Clinical data based on RET and RAS mutational status in sporadic MTCs.
RET+/RAS−
(%)
RET−/RAS−
(%)
RAS+/RET− 1 (%)
Median calcitonin level in pg/ml at diagnosis ()
700 (83–22931)
331 (20–42300)
402 (61–747)
0.01
Stage
I-II ()
18 (46%)
41 (71%)
7 (78%)
0.03
III-IV ()
21 (54%)
17 (29%)
2 (22%)
Lymph node metastases ()
21 (54%)
17 (29%)
2 (22%)
0.03
Biochemical cure2 ()
18 (46%)
38 (67%)
8 (89%)
0.03
Disease progression ()
9 (24%)
6 (10%)
0
0.08
Disease-related death3 ()
7 (18%)
2 (4%)
0
0.03
1One patient with a novel RAS mutation was excluded from statistical analysis. 2Ct level was unavailable for one patient. 3Two patients were lost to follow-up.
